Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

State Medicaid overpays for oxygen DME

This article was originally published in The Gray Sheet

Executive Summary

1HHS Office of Inspector General report claims that in six of nine states audited, Medicaid paid providers $12.7 mil. more than Medicare would have allowed for oxygen-related durable medical equipment. Analyses showed further cost savings could be achieved in the 41 non-audited states. CMS replies it cannot follow OIG's recommendation for alerting states to reduce Medicaid, since "these rates are not dictated or prescribed by CMS"...

You may also be interested in...



Home Oxygen Equipment Payment Reduction, Capped Rentals Needed – OIG

Home oxygen equipment should be subject to competitive bidding and capped rental arrangements in order to lower prices to Federal Employees Health Benefits or Medicare+Choice levels, according to a 1report from the HHS Office of Inspector General

Biogen Sees Improving Momentum In Slow Leqembi Launch

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT020744

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel